Sucampo Pharmaceuticals — Investor Presentation (January 2014)
14 slides from Sucampo Pharmaceuticals's investor presentation, Jan 13, 2014
Slide 1: AMITIZA U.S. Market Growth Accelerating
AMITIZA U.S. Market Growth Accelerating * Class up 5% YoY" + Takeda reported Q3 net sales at $72.5M*; 3.5% YoY increase in net sales to $204M through September + AMITIZATRx up 4% YoY through November YTD"; highest weekly TRx ever recorded in second week of December? OIC Opportunity 40-80% of non-can
Slide 2: AMITIZA U.S. (cont) Base Business Remains Strong
AMITIZA U.S. (cont) Base Business Remains Strong + 8M prescriptions over almost 8 years Building on strength in long-term safety + Resonates well with PCPs Building on strength in managed care access Preferred managed care position and significantly lower copay vs. competition Medicare Part D plan s
Slide 3: Global AMITIZA Approvals and Regulatory Filings
Global AMITIZA Approvals and Regulatory Filings | AMITIZA has been used for almost 8 years with 8M prescriptions by patients suffering from CIC and IBS-C Switzerland CIC (2009) OIC (filed) UK. CIC (2012) cont u OIC (filed) “nd OG : CIC (2006) IBS-C (2008) OIC Approved (April 2013) e 3 SUCAMPO The Sc
Slide 4: AMITIZA Global Snapshot
AMITIZA Global Snapshot. Japan Europe Sucampo Japan sales up * OIC filings in U.K. and 58.2% to $5.2M Q3 vs. Switzerland on track for | Q2 approval 1H 2014 + $10M ibution to . Sucampo topline for first in Switzerland as BAG* nine months of 2013 lifted several key | . | limitations to AMITIZA on June
Slide 5: AMITIZA Intellectual Property
AMITIZA Intellectual Property AMITIZA has a robust U.S. patent estate + 13 patents + Latest patents expire in 2027 Paragraph IV certification notice letter to Sucampo received on January 2, 2013 regarding ANDA submitted to FDA by Anchen Pharmaceuticals + Notice letter alleges the 126 claims in AMITI
Slide 6: RESCULA U.S. Overview
RESCULA U.S. Overview New RESCULA Commercial Strategy RESCULA prescriptions continuing to grow (strong growth in Q4)7 Commercialization focuses on current prescribers + 75% reduction in RESCULA Selling & Marketing expenses anticipated in 2014 Moving to contract sales organization for increased effic
Slide 7: Sucampo Prostone Pipeline Key Highlights
Sucampo Prostone Pipeline Key Highlights AMITIZA Clinical Development & Life Cycle Management New liquid dosage form + Initiated liquid formulation pivotal trial in CIC in adults October 2013; alternative treatment for patients who prefer not to take capsules + Takeda funding 100% of development cos
Slide 8: Sucampo Prostone Pipeline Key Highlights (cont.)
Sucampo Prostone Pipeline Key Highlights (cont.) lon Channel Activators for Lumbar Spinal Stenosis Lumbar Spinal Stenosis (LSS) Degenerative change in lumbar spine; unmet medical need with limited treatment options globally® More than 400,000 Americans, most >60 years of age, may be suffering from s
Slide 9: Clinical Pipeline & Product Development Highlights
Clinical Pipeline & Product Development Highlights CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT LEAD COMPOUNDS PRECLINICAL | PHASE 1 PHASE 2 PHASE 3 Lubiprostone Liquid Formulation CIC Unoprostone Isopropyl Retinitis Pigmentosa* Lubiprostone Pediatric Functional Constipation P2 Poc —2H14 4013 PO Ion
Slide 10: Key Facts & Financial Highlights
Key Facts & Financial Highlights Trading Symbol SCMP (NASDAQ) Corporate Headquarters Bethesda, MD Stock Price (01-09-14), 52-Week Range $9.12, $10.48 to $4.55 Shares 0} ing (01-09-14) 43.5M (1 class of common stock) Daily Volume (90-day average) 146,497 Market Capitalization (01-09-14) $397.1M Enter
Slide 11: Global Goals
v Global Q y vo AMITIZA prescua| us| Cee lon inel f Y Completed O In Progress Obtain approval of OIC sNDA: 1Q 2013 $10M milestone payment upon commercial launch of OIC Ongoing: Pursue strategic alliances; new AMITIZA indications/territories Grow sales in Japan in 2013 Submit for regulatory approval
Slide 12: Key Upcoming Events
Key Upcoming Events CEO Transition (EST) AMITIZA OIC indication potential approval in Switzerland / U.K. End of P3 lubiprostone liquid formulation study End of P1b study in cobiprostone for oral mucositis Start of Phase 1b study for oral ion channel activator in LSS The Scien
Slide 13: Key Facts & Financial Highlights
Key Facts & Financial Highlights Trading Symbol SCMP (NASDAQ) 4 9 ay of 2013 Corporate Headquarters | Bethesda, MD Debt $57.9M Stock Price (01-09-14), 52- | $9.12, $10.48t0 Gash & Equivalents $91.0M Week Range $4.55 Total Operating Expense | $49.1M Shares Outstanding (01-09- | 43.5M (1 class of Tota
Slide 14: References
References 1. IMS Smart View, NPA Report, client Factored Numbers, Is, NPA weekly data, DART Camille M. 0 challenges and Ams 2011 May; Clearview Analysis 2008 Fingertip Formulary (NOV 2013) Iss Smart View, RAPID Weekly, Client Factored Numbers 2 3 4 5. intemal Research 6 7 8. Sucampo data on fle 8 u
Sucampo Pharmaceuticals — Investor Presentation (January 2014) on 6ix